With this in mind, novel indices for measuring pain are required; ideally they should relate to an underlying aspect of pain transduction, take account of bio-psycho-social factors and translate between human and preclinical studies[6].
Schema theory guided the assumption that the two measures should be related.
Future studies should relate neural substrates of social cue processing in schizophrenia and relatives together with measures of social functioning.
We argue that longitudinal designs should relate the choice of timing and spacing of observations in longitudinal studies to characteristics of the processes being measured.
The outcomes being measured should clearly relate to a study's objectives, and need to be chosen and prioritised accordingly.
The US Food and Drug Administration FDA PRO Guidancece document [11] states that PRO measures should be conceptually valid as they relate to the medical intervention and disease state being studied, meet a threshold of psychometric soundness, and be relevant to patients.
These findings will be helpful for the prevention of HFRS, because they indicate that prevention and control measures should be targeted at the sites related with livestock husbandry.
In practice, these measures should be complemented by other measures more directly related to grasp properties.
In informal terms, all measures should be internally consistent; and the metric should be related to the concept being measured.
